With a year-over-year growth in debt of -86.76%, Aptevo Therapeutics Inc's debt growth rate surpasses just 2.21% of about US stocks.
In terms of volatility of its share price, APVO is more volatile than 99.66% of stocks we're observing.
Aptevo Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 121.06%, greater than the shareholder yield of 96.72% of stocks in our set.
Stocks that are quantitatively similar to APVO, based on their financial statements, market capitalization, and price volatility, are ADTN, OIIM, MNDO, PGNX, and MOSY.
Aptevo Therapeutics, a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company was spun off from Emergent BioSolutions Inc. in 2016 and is based in Seattle, Washington.
Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Ongoing Reports Preliminary Evidence of a Potential ...
SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on April 13, 2020 informing Aptevo that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Aptevo is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.
Advances Dose-Escalation Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Reports Preliminary Evidence of Clinical Activity of APVO436; Dosing ...
At present, dosing in cohorts 1 through 5 has been completed with dosing in cohort 6 scheduled to begin shortly. No evidence of dose-limiting toxicities was observed in the latest dose cohort (cohort 5.) A dose-limiting toxicity was observed in 1 of 6 patients in cohort 4.